Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44)
Post Date
July 22nd 2014
Application Due Date
May 7th 2017
Funding Opportunity Number
PAR-14-292
CFDA Number(s)
93.121
93.213
93.242
93.273
93.279
93.853
93.865
Funding Instrument Type(s)
Cooperative Agreement
Funding Activity Categories
Education
Health
Income Security and Social Services
Eligibility Categories
Other Eligible Applicants include the following: Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria: 1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; 2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; 3.Ф(i) SBIR and STTR.ФBe a concern which is more than 50 percent directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50 percent directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR (ii) SBIR-only.ФBe a concern which is more than 50 percent owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these.ФNo single venture capital operating company, hedge fund, or private equity firm may own more than 50 percent of the concern; OR (iii) SBIR and STTR.ФBe a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with _ 121.705(b) concerning registration and proposal requirements. 4.ФHas, including its affiliates, not more than 500 employees.
Funding
-
Award Range:
$None - $None
Grant Description
The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
National Institutes of Health
-
Agency Contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV -
Agency Mailing Address:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Agency Email Address:
- More Information:
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: